AI Insight
Researchers have discovered that the protein C3, which evolved before the development of blood circulation systems, can enhance cancer immunotherapy effectiveness when produced inside tumors. The protein works by blocking immune-suppressing cells that typically prevent immunotherapy from attacking cancer. In mouse models, scientists successfully induced C3 production in treatment-resistant tumors, resulting in significantly improved survival rates.
Why it matters
This discovery could lead to new combination therapies that overcome immunotherapy resistance, a major challenge in cancer treatment. By manipulating C3 levels within tumors, researchers may be able to help patients who currently do not respond to existing immunotherapy approaches.
Understand the Science
A protein that evolved long before the human circulatory system may help unlock stronger cancer treatments. When C3 is produced inside tumors, it blocks immune-suppressing cells and gives immunotherapy a better chance to work. Researchers were even able to recreate this effect in resistant tumors, significantly improving survival in mice.
Source: A protein older than blood circulation could transform cancer immunotherapy